🦠 Probiotic Strain Specificity Clinical Evidence Simulator
This simulation examines the specific strains of probiotics and their clinical effectiveness in managing symptoms of Irritable Bowel Syndrome (IBS). It highlights the importance of selecting the right probiotic strain based on scientific evidence to achieve optimal therapeutic outcomes.
Species-Level Claims Hide the Real Evidence
A label saying "Lactobacillus" promises nothing clinically specific.
- L. rhamnosus: Species claimed (generic label)
- 50+: Strains in species (genetically distinct)
- 0%: Evidence transfer (not automatic)
- 1 strain: Trials behind claim (not the species)
Species is a taxonomy rank, not a guarantee
Species names group related bacteria, not identical clinical effects.
Marketing shortcuts the science
Labels often list species only, skipping the studied strain code.
Consumers assume equivalence
People wrongly assume any strain of the species works the same.
Strains of One Species Can Differ Enormously
Strain genomes diverge in genes that shape clinical behavior.
- 10-30%: Genome variation (gene content differs)
- Variable: Plasmid content (strain-specific genes)
- Strain-unique: Surface proteins (adhesion differs)
- ~70%: Shared core genome (rest is strain-specific)
Core genome vs. accessory genome
A shared core leaves plenty of room for strain-specific genes.
Horizontal gene transfer adds variation
Strains pick up unique plasmids and mobile genetic elements.
Phenotype follows genotype
Different genes produce different surface, metabolic, and immune behaviors.
A Strain's Own Genes Drive Its Clinical Effect
Clinical benefit traces back to one strain's unique toolkit.
- GG only: Adhesion pilus gene (mucus adhesion)
- LC705: Bile salt hydrolase (different strain)
- Rare: Shared mechanism (not species-wide)
- Unique genes: Effect source (drive clinical result)
Adhesion determines gut persistence
Pilus genes let one strain stick to mucus better than others.
Metabolite output varies by strain
Bacteriocins, enzymes, and EPS output differ strain to strain.
Mechanism, not species, causes the effect
The clinical result maps to a mechanism, not the species label.
Trials Prove One Strain — Not the Whole Species
Randomized trials are strain-coded; extrapolation is unsupported.
- 100+: RCTs on strain GG (diarrhea prevention)
- 0: RCTs on other strains (for same claim)
- No: Evidence transferable (strain-specific only)
- Strain-coded: Meta-analyses (must match exactly)
Trial registries record exact strain codes
Study protocols specify the strain, batch, and dose used.
Substituting strains breaks the evidence chain
Swapping strains invalidates the trial's clinical conclusions.
Regulators increasingly require strain ID
Some agencies now demand strain-level substantiation for health claims.
Correct Claims Name the Exact Strain
Trustworthy labels pair species, strain code, and the studied effect.
- Strain + species: Correct label (full identification)
- Invalid: Species-only claims (insufficient evidence)
- Strain ID: Regulatory standard (required for claims)
- Read label: Consumer action (check exact strain)
Look for the strain code
A trustworthy label reads like "L. rhamnosus GG," not just genus.
Match the claim to the trial
Check that the advertised benefit matches the strain that was studied.
Species-level marketing is a red flag
Missing strain codes should lower confidence in any health claim.
This simulation examines the specific strains of probiotics and their clinical effectiveness in managing symptoms of Irritable Bowel Syndrome (IBS). It highlights the importance of selecting the right probiotic strain based on scientific evidence to achieve optimal therapeutic outcomes.
2D · HTML5 Canvas 2D · 60 FPS target · runs fully client-side, no install